NathanH.FowlerMD

PubMed

• Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.
  Ashwath Gurumurthi, Collin K Chin, Lei Feng, Nathan H Fowler, Paolo Strati
  Eclinicalmedicine. 2024-08-01
• 20 citations
  Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
  Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad
  Blood. 2024-04-25
• Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 s...
  Max J Gordon, Lei Feng, Paolo Strati, Hun Ju Lee, Fredrick B Hagemeister
  Cancer. 2024-03-15

Journal Articles

• Venetoclax, Bendamustine, and Rituximab in Patients with Relapsed or Refractory NHL: A Phase 1b Dose-Finding Study  
  N Fowler, E Reid, L J Nastoupil, Annals of Oncology

Abstracts/Posters

• Predictive Factors of Response and Survival of Lenalidomide and Rituximab As Initial Treatment of Follicular Lymphoma
  Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
  Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110_/_ Inhibitor in Patients with Relapsed/Re...
  Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Analysis of an Online Treatment Decision Tool Reveals Variances in Practice between Experts and Oncology Healthcare Providers for Newly Diagnosed Follicular Lymphoma
  Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Subgroup Analyses of Elderly Patients Aged _ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo...
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
  Nathan H. Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
  Nathan H Fowler, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed p... 
  2019 ASCO Annual Meeting - 6/1/2019
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Seven Year Follow up and Comparison of Dosing Strategies from the Pivotal Phase II Clinical Trial of Lenalidomide Plus Rituximab (R) in Previously Untreated Follicular... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Prognostic Factors, Outcomes and Clinical Characteristics in Patients with Transformed Follicular Lymphoma (t-FL): Cohort Study of Patients 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib E... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL). 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previ... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• Join now to see all